))
Weight Loss and CV Outcomes with Ozempic, Munjaro and Similar Drugs with Dr. Peter Toth
Manage episode 362098795 series 3336137
Content provided by Thomas Nero, MD, Thomas Nero, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Thomas Nero, MD, Thomas Nero, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr Peter Toth discusses with Dr. Thomas Nero the new classes of diabetes medications, SGLT2 inhibitors (eg Jardiance) and GLP1 receptor agonists (eg Ozempic and Munjaro.) These drugs have been in the news due to an impressive effect on weight reduction, but they also improve cardiovascular outcomes in diabetic and non-diabetic patients.
20 episodes
Share
